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Abstract 
Objective: The effectiveness of leaf concentrate powder (LCP) as a nutritional supplement 
was established in trials conducted among adolescent girls and pregnant women in India. 
Here we evaluate LCP, compared with skimmed milk powder (SMP), as a supplement for 
antiretroviral-naïve children living with HIV in a sub-Saharan African country. 
Design: Randomized controlled two-arm 6-month trial comparing effects of isoproteic (5g) 
LCP (10g daily) and SMP (15g daily) on HIV-1 viral load, CD4+ cell count/percentage, 
weight/height-for-age, general blood parameters, diarrhea, respiratory and HIV-related 
opportunistic infections. 
Setting: Bujumbura and Kirundo, Burundi. 
Subjects: 83 HIV+ ART-naïve children age 5-14 years: median (range) CD4 count 716 (361-
1690) cells/mm3; log10 HIV-1 viral load 4.39 (1.79-6.00). 
Results: LCP was equivalent to SMP in relation to HIV-specific blood parameters, and did 
not demonstrate superiority over SMP in relation to Hb. Three children in each arm (LCP 
7.1% (3/42); SMP 7.3% (3/41)) proceeded to ART because their CD4 counts fell below 350 
cells/mm3. Children in the LCP group reported higher levels of appetite and overall health at 
6 months. There were no differences in clinical events or any other outcome measures. LCP 
was less palatable than SMP to the children in this population, but there were few negative 
perceptions of appearance, texture and taste. 
Conclusions: LCP appears to be equivalent to SMP as a nutritional supplement in this 
population, despite slightly lower palatability. In relation to viral load and CD4 count, 
equivalence may indicate no effect in either group. Effectiveness relative to no 
supplementation remains to be determined. 
Introduction 
Maintaining good nutritional status among HIV-infected children is clearly of paramount 
importance(1). WHO guidelines for incorporating nutritional support into care programs for 
HIV-infected children are available for local adaptation(2), and nutritional support services 
appear to be generally available at HIV care and treatment sites in sub-Saharan Africa(3). 
However, the evidence-base for the effectiveness of specific nutritional interventions in HIV-
infected children is weak(4), and nutritional interventions impose additional costs on HIV care 
programs(5). 
 
These costs could be reduced by developing locally-produced food-based supplements, which 
are also likely to be more palatable and culturally acceptable. Leaf concentrate is a food-
based nutritional supplement(6) which has been shown to be effective at preventing anemia in 
adolescent girls(7) and pregnant women(8) in India. Although anemia may actually be less 
prevalent among HIV-infected than among uninfected children(9), it remains an important 
comorbidity and, together with other nutritional deficiencies and diarrheal disease, is a strong 
predictor of poor outcomes among children after initiation of antiretroviral therapy (ART)(10; 
11; 12). 
 
Leaf concentrate was discovered in France in the 18th century, and was developed as a 
foodstuff in England between 1940-1970(13). It has since been promoted by several non-
governmental organizations, including Leaf for Life in the USA(14) and the Association pour 
la Promotion des Extraits Foliaires en Nutrition (APEF) in France(15), as a sustainable form of 
protein and micronutrient supplementation for low-income communities(6). In this study, we 
investigate the potential benefits of dried lucerne (alfalfa) leaf concentrate as a nutritional 
supplement for HIV-infected ART-naïve children living in two cities in Burundi. The aim of 
the study was to determine the acceptability and palatability of leaf concentrate, and to 
measure its effectiveness (compared with skimmed milk powder) in relation to HIV-specific 
(viral load, CD4+ count) and general (haematological, anthropometric) parameters, and 
overall health. 
Methods 
Study population and recruitment 
Our target population was antiretroviral-naïve HIV-positive children age 5-14 years. Children 
were recruited from two clinical centres (in Bujumbura and Kirundo) run by the Association 
Nationale de Soutien aux Séropositifs et malades du Sida (ANSS, National Association of 
Support for People Living with HIV and AIDS). Founded in 1993, ANSS’ mission is to 
promote the prevention of HIV transmission and to improve the well-being of people living 
with and affected by HIV. The ANSS was the first Burundian civil society organization to 
provide HIV services to people living with HIV, including the distribution of antiretroviral 
therapy. At the end 2013, the ANSS was providing treatment to more than 6,000 people in 
Burundi. From 2007 to 2013, the association provided HIV counselling and testing to more 
than 56,000 people as part of its HIV prevention efforts. Recruitment was conducted by 
medical staff at the two centres, who identified eligible children at routine clinic 
appointments to which HIV-positive children are invited for medical and psychosocial 
monitoring purposes. The same staff explained the purpose of the study to children and their 
parent(s)/guardian(s), who were provided with a study information sheet and consent form in 
the local language (Kirundi). 
 
Ethical approval, trial registration and consent 
Ethical approval for the study was granted on 16/06/2012 by the “Comité National d’Ethique 
pour la protection des êtres humains participants à la recherche biomédicale et 
comportementale” of Burundi. Written informed consent was obtained from the 
parent(s)/guardian(s) of eligible children, with original consent forms being held by ANSS. 
 
Inclusion criteria 
Children were eligible if they were ≥5 and ≤14 years old, had tested positive for HIV-1 (HIV 
1/2 STAT-PAK® DIPSTICK Assay, Chembio Diagnostic Systems, Inc., 3661 Horseblock 
Road, Medford, NY 11763, USA), and had a CD4+ cell count ≥350 cells/mm3(16). Children 
with a CD4+ cell count <500 cells/mm3 were required to receive prophylactic 
sulfamethoxazole/trimethoprim(2). All children were dewormed before the study began using 
an appropriate dose of albendazole. 
 
Exclusion criteria 
Children were ineligible if they had a major concurrent illness (e.g. cancer, tuberculosis or 
diabetes), a BMI <12 kg/m2, were liable to move out of the study area or were unlikely to be 
able to receive the weekly supplements, or had participated in a clinical trial in the preceding 
3 months. 
 
Primary and secondary outcomes 
Primary outcomes were percentage of CD4+ T lymphocytes, HIV viral load, and Hb 
measured after 6 months of follow-up. Secondary outcomes (also measured at 6 months) 
included: anthropometric indices (height-for-age, weight-for-age, handgrip strength); 
episodes of illness (diarrhea, respiratory); overall health (anemia, inflammation (CRP); 
fatigue, appetite); and palatability of the supplements (appearance, texture, taste). 
 
Sample size 
We aimed to recruit 42 children into each arm of the trial. This sample size was calculated to 
yield 90% power at a 5% level of significance to detect: a) equivalence between LCP and 
SMP in percentage of CD4+ T lymphocytes at 6 months, by excluding a difference in means 
of 5% (assuming that the standard deviation (SD) in the outcome = 7%); b) equivalence 
between LCP and SMP in log10 HIV viral load, by excluding a difference in means of 0.5 
(assuming SD=0.7 and 15% of participants lost to follow-up); c) superiority of LCP over 
SMP in increasing mean Hb from 115g/L (SD 14g/L) to 125g/L (SD 14g/L), compared with 
no change in SMP arm (because LCP provides 5.4mg Fe compared with 0.1mg Fe in SMP). 
 
Randomization, allocation and adherence 
Eligible children with consent to participate were allocated to LCP or SMP using a computer-
generated random number sequence and consecutively-numbered sealed envelopes. 
Envelopes were held and opened by a member of ANSS administrative staff not otherwise 
involved in the study, i.e. allocation was concealed from the ANSS medical staff who were 
running the trial. Delivery of supplements to all participants were made by ANSS health 
workers at an interval of 2 weeks and were recorded for each child. Observance of 
supplement consumption was monitored and discussed collectively (with all children and 
their parents) at each monthly monitoring visit in order to highlight difficulties and elaborate 
solutions. For the few parents who were not present at a supplement delivery time or reported 
difficulties in supplement consumption by their child, ANSS health workers visited them at 
home to see how supplements were consumed. 
 
Leaf concentrate powder 
The LCP group received 10g of lucerne (Medicago sativa) leaf concentrate powder (France-
Luzerne Agricultural Co-operative, 51130 Aulnay-aux-Planches, France). The leaf 
concentrate was contained in sachets, and could be taken orally by mixing with water or tea. 
The composition of the LCP is shown in Table 1. 
 
Skimmed milk powder 
The SMP group received 15g of skimmed milk powder (Société Industrielle Laitière du Léon, 
Le Raden, 29860 Plouvien, France). The skimmed milk powder was given in a sachet which 
could be taken orally by mixing with water or tea. The composition of the SMP is shown in 
Table 1. 
 
HIV-specific parameters and non-specific blood parameters 
HIV-1 viral load, absolute count and percentage of CD4+ T lymphocytes (CD4%), and 
general blood parameters (Hb, WBC, lymphocytes, platelets, and CRP) were measured at 
baseline, 3 and 6 months in blood samples which were collected at ANSS clinics and 
transferred to the National Institute of Public Health (INSP), Rivubu Avenue, Bujumbura and 
to a laboratory at the New Hope Centre, Bujumbura. HIV viral load was measured at INSP 
using real-time PCR (Abbott RealTime HIV-1 assay, Abbott Laboratories. Abbott Park, 
Illinois, USA). CD4 absolute count and percentage was measured at the New Hope Centre 
using BD FACS Count (BD Biosciences, 2350 Qume Drive, San Jose, CA, USA). Non-
specific blood parameters were measured at INSP. Anemia was defined as Hb <115g/L, 
CRP-positivity as CRP ≥6mg/L. 
 
Anthropometric parameters 
Weight and height were measured using electronic scales and standing measurement boards 
during clinic visits at baseline, 3 and 6 months. Height-for-age and weight-for-age z-scores 
were estimated against British 1990 (UK90) growth charts(17; 18). The UK90 BMI reference 
provides centile curves for children from birth to 23 years, based on a sample of 32,222 
measurements from 12 distinct surveys in British children collected between 1978 and 1994. 
Handgrip strength was measured, using a Jamar® hydraulic hand dynamometer (Patterson 
Medical, Nottinghamshire, UK), by two successive trials on the dominant side with the elbow 
at 90°, the maximal score of the two trials being recorded. 
 
Diarrhea, respiratory infection, appetite, fatigue and overall health levels 
Diarrhea, respiratory infection and other illnesses were recorded by ANSS clinicians monthly 
and during clinic visits at baseline, 3 and 6 months. Disease occurrences and corresponding 
treatments were recorded for each child in order to detect the medical events during each 
three months period (0-3months, 3-6months). Appetite, fatigue and overall health were 
assessed by questioning parents/carers at baseline, 3 and 6 months, with the following 
possible responses: fatigue (none, moderate, severe); appetite (weak, satisfactory, good, very 
good); overall health (very poor, poor, satisfactory, good, excellent). 
 
Palatability 
Three aspects of palatability (appearance, texture and taste) were recorded by ANSS health 
workers during clinic visits at 3 and 6 months, with the following possible responses: 
appearance (unappealing, acceptable, appealing, very appealing); texture (unappealing, 
acceptable, appealing, very appealing); taste (very bad, bad, acceptable, good, very good). 
 
Statistical analyses 
Data were entered into a computer using Microsoft Excel, and were analyzed using Stata 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). 
Between-group differences in continuous outcome measures were estimated using linear 
regression models. Between-group differences in binary outcome measures were tested using 
Fisher’s exact tests. We fitted linear regression models using generalized estimating 
equations for each continuous outcome measure, including an interaction term between study 
arm and time-point (0, 3 or 6 months) to estimate within- and between-group changes at each 
time-point. We used an exchangeable within-child correlation structure (which assumes that 
the observations within a subject are equally correlated), and we verified by inspection that 
other correlation structures (ar1 and ar2) did not produce different results. 
 
Results 
Characteristics of trial participants 
The median age of the participants was 10 years (range 5 to 14 years) and 39.8% (33/83) 
were male (Table 2). 42 children were randomized to receive SMP, and 41 to LCP (Figure 
1). 
 
Loss to follow-up and adherence 
One child in the SMP arm and two children in the LCP arm did not receive their allocated 
intervention and dropped out at the beginning of the trial (Figure 1). One child in the LCP 
arm dropped out just after the 3-month follow-up. Three children in each arm had an HIV 
viral load <350cells/mm3 measured at the 3-month follow-up and proceeded to receive 
antiretroviral therapy. At 6 months, primary and secondary outcome measures were available 
for 90.5% (38/42) and 85.4% (35/41) of participants in the SMP and LCP groups, 
respectively. The final analysis was performed on the 38 SMP and 35 LCP children who had 
data on one or more outcome measures at the 6 months follow-up. 
 
Blood parameters 
The 95% confidence intervals of the between-group differences in percentage of CD4+ T 
lymphocytes and HIV-1 viral load at 6 months suggested non-equivalence between SMP and 
LCP (Table 3). For CD4+ percentage, equivalence had been defined as a difference not 
greater than 5%, but the 95% CI for the between-group difference in this parameter at 6 
months was -1.17% to 6.07%, i.e. the upper bound exceeded 5% (in favour of LCP). 
Similarly, equivalence for HIV viral load had been defined as a difference not greater than 
0.5 logs, but the 95% CI of the observed difference was -0.19 to 0.67, i.e. the upper bound 
exceeded 0.5 (in favour of SMP). However, the 95% CI for the baseline values of these two 
HIV-related measures were also consistent with non-equivalence (suggesting the role of 
chance). Adjusted for baseline, the between-group differences at 6 months for CD4+ 
percentage and HIV viral load were 0.59% (95% CI -1.42% to 2.61%) and 0.18 (-0.08 to 
0.44), respectively. These differences and their 95% confidence intervals are consistent with 
equivalence between SMP and LCP. 
 
The estimated additional effects of LCP (compared with SMP) on the changes in CD4+ 
percentage and HIV viral load over 6 months indicate no additional effect of LCP: for CD4+ 
percentage, 0.97% (95% CI -0.86%, 2.80%), P=0.30; for log10 HIV viral load, 0.20 (-0.03, 
0.43), P=0.09. LCP was not superior to SMP in improving Hb, with similar increases over the 
6 months in both arms, and no additional effect of LCP compared to SMP (-1.71 (95% CI -
6.49 to 3.07) g/L, P=0.48). LCP did not have any additional effect over SMP on 0-6 month 
changes in any of the other blood parameters (Supplementary Table 1). 
 
We found only slight changes in the interaction (adjusted 0-6 month change) estimates and 
their confidence intervals when we used ar1 and ar2 autoregression correlation structures, 
instead of an exchangeable (exch) structure: percentage CD4+ T lymphocytes, exch 0.97% (-
0.86%, 2.80%), ar1 0.98% (-0.93%, 2.88%), ar2 0.90% (-1.03%, 2.83%); log10 HIV-1 viral 
load, exch 0.20 (-0.03, 0.43) , ar1 0.19 (-0.04, 0.43), ar2 0.23 (-0.01, 0.46); Hb exch -1.71 (-
6.49, 3.07) g/L, ar1 -2.14 (-7.20, 2.91) g/L, ar2 -1.51 (-6.47, 3.45) g/L. 
 
Anthropometric parameters 
Height-for-age and weight-for-age Z-scores increased to the same degree in both groups of 
children over the 6 months, and there was no additional effect of LCP over SMP (Table 4). 
There were no between-group differences in median handgrip strength scores at 3 or 6 
months, but children in the LCP group increased their (geometric mean) handgrip strength 
score 2.4-fold over the 6 months, compared with no change in the SMP group (Table 4). 
 
Diarrhea, respiratory infection and other illnesses 
There were few reported cases of diarrhea during the study in either group: in the LCP group, 
4 cases at baseline, then 1 case during 0-3 months and 1 case during 3-6 months follow-up; in 
the SMP group, 3 cases at baseline, no cases during 0-3 or 3-6 months follow-up. Pneumonia 
was reported to be present only once in each group, in both cases, during 3-6 months follow-
up. ENT infections (angina, ear infection) occurred in 2 LCP group children and in 5 SMP 
group children. Malaria was diagnosed during an acute clinic access by 2 children of the LCP 
group and 3 children of the SMP group. 
 
Anemia, inflammation, fatigue, appetite and overall health 
Overall prevalence of anemia (Hb<115g/L) fell from 39.7% (29/73, 95%CI 28.5-51.9%) at 
baseline to 24.7% (18/73, 15.3-36.1%) at 3 months and 20.6% (15/73, 12.0-31.6%) at 6 
months, with similar prevalence in both groups at each time-point. CRP-positivity fell from 
23.3% (17/73, 14.2-34.6%) at baseline to 15.1% (11/73, 7.8-25.4%) and 9.6% (7/73, 3.9-
18.8%) at 3 and 6 months, respectively, again with no detectable between-group differences 
(Supplementary Table 2). Appetite and overall health appeared to be better at 6 months in 
the LCP group, although there were no differences if the responses “very good” and “good” 
to the appetite question were merged (92.1% (35/38, 78.6-98.3%) in the SMP group 
compared with 97.1% (34/35, 85.1-99.9%) in the LCP group, P=1.00) and if the “excellent” 
and “good” overall health responses were merged (73.7% (28/38, 56.9-86.6%) in the SMP 
group compared with 85.7% (30/35, 69.7-95.2%) in the LCP group, P=0.31). 
 
Palatability 
The appearance, texture and taste of SMP were rated more favourably than for LCP. All 
(38/38) of participants in the SMP arm rated appearance and texture as appealing/very 
appealing at 3 and 6 months, and 97.4% (37/38, 95% CI 86.2-99.9%) and 97.3% (36/37, 
85.5-99.9%) rated taste as good/very good at 3 and 6 months, respectively (Supplementary 
Table 3). In contrast, 80.0% (28/35, 63.1-91.6%) and 82.9% (29/35, 66.4-93.4%) of 
participants in the LCP arm rated appearance and texture as appealing/very appealing, and 
77.1% (27/35, 59.9-89.6%) rated taste as good/very good at 3 months. At 6 months, 85.7% 
(30/35, 69.7-95.2%) and 80.0% (28/35, 63.1-91.6%) rated the appearance and texture of LCP 
as appealing/very appealing, and 68.6% (24/35, 50.7-83.1%) the taste as good/very good. 
There were fewer negative ratings of the palatability of LCP at 6 compared with 3 month, but 
with insufficient numbers to provide statistical evidence of change: unappealing appearance 
11.4% (4/35, 3.2-26.7%) to 0.0% (0/35); unappealing texture 5.7% (2/35, 0.7-19.2%) to 2.9% 
(1/35, 0.1-14.9%); and bad taste 17.1% (6/35, 6.6-33.6%) to 11.4% (4/35, 3.2-26.7%). 
 
Discussion 
During 6 months of follow-up in this population of HIV-positive ART-naïve children, LCP 
was equivalent to SMP, after adjustment for baseline values, in relation to HIV-specific blood 
parameters (which showed little or no change in either group), and did not demonstrate 
superiority over SMP in relation to Hb levels (which increased in both groups). Higher levels 
of appetite and overall health were reported for children in the LCP group, and they also had 
higher handgrip strength scores. There were no differences in any of the other outcome 
measures. In terms of palatability, LCP was less acceptable than SMP to the children in this 
population, but with few negative ratings of appearance, texture and taste. 
 
Our study was powered to detect equivalence in relation to HIV-specific blood parameters 
(CD4% and HIV viral load), and superiority in relation to Hb levels (because of the higher 
iron content of LCP). Differences between the two groups at baseline (which could only have 
arisen by chance) exceeded the thresholds for equivalence, suggesting that a wider a priori 
equivalence interval was required. However, the fully-adjusted analysis using longitudinal 
linear regression models gave estimates which were consistent with equivalence in the 
primary outcome measures. No differences were detected in any of the other outcome 
measures, although assessment of ‘appetite’, ‘overall health’ and handgrip strength at 6 
months appeared to favour LCP. Several participants were lost to follow-up from each arm of 
the study, which would have reduced the power of the study, and the study was not sized to 
detect pre-specified differences in the secondary outcome measures. Allocation to the 
supplementation arms was concealed, but children and their parents/carers and field workers 
were not blinded to allocation. 
 
In the fifteen or so years since paediatric HIV came to be regarded as a chronic disease(19), 
very little research has been conducted into the nutritional aspects of HIV infection in 
children age ≥5 years. Even for children under 5 years old, the evidence-based for nutritional 
interventions remains weak. The most recent Cochrane review reported some evidence for 
beneficial effects of vitamin A, zinc and micronutrient supplements, based on seven trials in 
sub-Saharan African countries(4). This dearth of evidence may have arisen because children 
and adolescents fall into a gap between research into HIV infection during pregnancy and 
infancy (because of the focus on vertical transmission) and during adulthood (wherein lies the 
main ‘burden’ of HIV infection, in terms of numbers of people infected), or it may have 
arisen because nutritional interventions have proven to be less effective than expected, given 
observational evidence for the importance of nutrition among people infected with HIV(20). 
 
In policy terms, it has been acknowledged that children, together with adolescents (girls in 
particular), are being “left behind” in global efforts to end the AIDS epidemic(21). This may 
be attributable in part to success in reducing the incidence of new infections in children, 
which have fallen by 58% from a peak of 580,000 in 2002. However, in 2013 there were an 
estimated 240,000 new infections, and 3.2 million children under 15 were living with HIV, 
91% of whom were in sub-Saharan Africa. Given that these children are more likely to live in 
food-insecure households(1), that HIV infection is associated with faltering growth to at least 
10 years of age(22), and that micronutrient sufficiency might be an important adjunct to anti-
retroviral therapy(23), effective and sustainable approaches to maintaining adequate nutrition 
for HIV-infected children in resource-poor settings should be a priority area for research. 
 In the absence of comparable studies of nutritional interventions among ART-naïve children 
age 5-14 years, and because our study did not have an unsupplemented control group, we can 
only conclude that children receiving leaf concentrate and dairy supplements had equivalent 
outcomes in terms of CD4 percentage and HIV viral load. We cannot conclude that either 
supplement had any effect on these two outcomes, i.e. equivalence may indicate lack of 
effect. The higher iron content of the leaf concentrate supplement did not have any additional 
effect on Hb levels, for which there was evidence of improvement in both groups. This result 
may be attributable to the relatively normal baseline hemoglobin levels and/or to the 
consumption of LCP within tea (an inhibitor of iron absorption). Similar improvements in 
inflammation and fatigue were detected in both arms. Although both supplements contained 
zinc, the amounts are unlikely to have had an effect on diarrhea, for which some evidence of 
a protective effect of zinc supplementation has been reported(4). The leaf concentrate 
supplement contained much higher levels of β-carotene than did the skimmed milk powder, 
but our study was not designed to detect differential effects of leaf concentrate on outcomes 
such as diarrhea and cough, for which evidence of beneficial effects of vitamin A 
supplementation is reasonably consistent(4).  
 
That growth indices improved in both groups is reassuring, given the accuracy with which 
these outcomes can be measured and the 6-month duration of our study. Classical 
anthropometric indices improved to the same degree in both groups, whereas handgrip 
strength score increased at a higher level in the LCP group. These data, combined with 
impact on appetite and overall health, suggest that LCP may increase the nutritional status 
more efficiently than SMP, because a relationship has been highlighted between muscle mass 
and function in children(24; 25). These differences need to be confirmed by a larger study, 
ideally comparing LCP to no supplement (or to a supplement with known effects), and 
perhaps providing larger amounts of supplement or in conjunction with other nutrients. 
 
HIV-infected adults have increased energy requirements(26), and additional calories are 
recommended by WHO for HIV-positive children(27), particularly in children experiencing 
weight loss. In our study, even greater gains in height and weight might have been achieved 
had the supplements been used to fortify a calorific snack, something which should be 
considered for future trials in this population. Incorporating the supplements into isocaloric 
biscuits could also address the issue of blinding (if the non-LCP biscuits were dyed green), 
and might improve adherence and acceptability(28). The calcium content of both supplements 
might be expected to ameliorate low bone mass, an effect of HIV infection that has been 
reported for children and adolescents(29), although longer follow-up would probably be 
required to detect any such effects. Trials which aim to test novel dietary interventions would 
benefit from information obtained from qualitative research into local tastes and 
preferences(30). Such research would, ideally, be conducted before the trial, but could also be 
conducted during the trial. 
 
Leaf concentrate might be considered as a candidate ingredient for the food multimix (FMM) 
concept(31). The aim of FMM is to combine locally-available and commonly-consumed food 
ingredients into a culturally-acceptable end product which makes the best use of each 
ingredient’s nutritional ‘strengths’. Although our study compared LCP against SMP, parallel 
production of the two supplements is rendered eminently feasible by the unique capacity of 
the leaf fractionation concept to provide direct access to the edible fraction of the leaves and 
to provide feed for livestock.  For example, lucerne grown on 1 hectare can generate the 
production of 2,000 kg of SMP if consumed directly by cattle; the same lucerne, fractionated 
into LCP for human consumption, fibre cake and whey for cattle can still produce 1,800 kg of 
SMP, with the added production of 1,200 kg of LCP(6). In this context, our demonstration that 
the nutritional qualities of SMP and LCP are comparable is an important finding. 
 
The acceptability of leaf concentrate, and any economic advantage that it may have over 
industrially-sourced skimmed milk powder, remains to be determined. Much as local and 
sustainable production of leaf concentrate is espoused as a key selling point(6), this remains 
somewhat theoretical, and the development of the leaf fractionation concept is an ongoing 
process. In the case of Burundi, as in many tropical and sub-tropical countries, vegetables 
constitute a far greater component of the traditional diet than dairy products(32), and vegetable 
crops (including those with leaves which are suitable for leaf concentrate production, e.g. 
beans) are one of the main agricultural products(33). 
 
These uncertainties should not deter further pursuit of alternative food-based solutions, 
including leaf fractionation, to nutritional problems among impoverished and vulnerable 
communities, particularly where local resilience might be needed in the face of endemic food 
insecurity and episodic civil instability(34; 35). In the meantime, our small study in a 
particularly vulnerable group has demonstrated that a leaf-derived food supplement could 
meet this need as effectively as a conventional milk-based supplement. 
Table 1: Composition (mean ± SD) of leaf concentrate and skimmed milk powders 
Nutrient Leaf concentrate powder 
(per 10g sachet)(36) 
Skimmed milk powder* 
(per 15g sachet) 
Protein 5.1  0.46 g 5.2 g 
Fat 1.0  0.1 g 0.1 g 
Linoleic acid (omega-6)† 12.2  0.8 %  
α-linolenic acid (omega-3)† 34.1  4.5 %  
Carbohydrates 0.1  0.02 g 7.8 g 
Iron 5.4  0.86 mg 0.072  0.02 mg 
Folic acid 13.4  7.3 μg 10.3  4.6 µg 
β-carotene‡ 767  382 μg 1.4  0.6 µg 
Vitamin E 9.9  1.9 mg 3.9  2.0  µg 
Vitamin C 6mg§ 1.24  0.4 mg 
Calcium 338  43 mg 185  29 mg 
Copper 76  10 μg 9.0  3 mg 
Manganese 0.6  0.06 mg 6.6  3 µg 
Zinc 0.2  0.08 mg 0.63  0.05 mg 
* French Agency for Food, Environmental and Occupational Health and Safety 
(https://pro.anses.fr/TableCIQUAL/, accessed 03/07/2015) 
†percentage of fat content 
‡retinol activity equivalents (RAE) 
§corresponding to ascorbic acid added during manufacturing to prevent oxidation 
 
Table 2: Characteristics of children in each arm at the beginning of the study (baseline) 
 Skimmed milk (n=42) † Leaf concentrate (n=41) † 
Site Bujumbura 25 (59.5%) 24 (58.4%) 
Kirundo 17 (40.5%) 17 (41.5%) 
Sex (male) 15 (35.7%) 18 (43.9%) 
Age (years) 10 (8 to 11) 10 (8 to 12) 
Height-for-age Z-score -1.10 (-2.05 to -0.39) -1.47 (-1.95 to -0.74) 
Weight-for-age Z-score -1.33 (-2.36 to -0.54) -2.20 (-1.58 to -0.81) 
Handgrip strength score (kg) 12 (8 to 15) 13 (10 to 16) 
Log10 HIV-1 viral load 4.39 (3.74 to 5.13) 4.39 (4.03 to 4.74) 
Number of CD4+ T lymphocytes (cells/µL) 723 (606 to 966) 678 (523 to 895) 
Percentage of CD4+ T lymphocytes (%) 27.0 (21.5 to 30.8) 27.9 (24.5 to 32.6) 
Haemoglobin (g/L) 117 (110 to 127) 119 (111 to 125) 
Presence of diarrhea 4 (9.5%) 3 (7.3%) 
Presence of respiratory infection 0 (0.0%) 0 (0.0%) 
CRP positive (≥6mg/L) 11 (26.2%) 10 (24.4%) 
† Values are frequency (%) or median (IQR). 
Table 3: Percentage of CD4+ T lymphocytes, HIV-1 viral load and Hb at baseline, 3 
and 6 months* 
 Skimmed milk 
powder group 
(n=38) 
Leaf concentrate 
powder group 
(n=35) 
Between-group 
difference† 
Percentage of CD4+ T lymphocytes (%) 
Baseline (n=37, 35) 26.6 (24.3, 29.0) 28.6 (26.3, 31.0) 1.96 (-1.29, 5.22) 
3 months (n=38, 33) 25.1 (22.8, 27.4) 27.9 (25.1, 30.7) 2.76 (-0.75, 6.27) 
6 months (n=38, 34) 26.4 (23.9, 28.8) 28.8 (26.1, 31.6) 2.45 (-1.17, 6.07) 
0-6 month change -0.24 (-1.36, 0.88) 0.29 (-1.30, 1.89) 0.53 (-1.41, 2.48) 
Adjusted 0-6 month change‡ -0.01 (-1.32, 1.30) 0.96 (-0.72, 2.65) 0.97 (-0.86, 2.80) 
    
Log10 HIV-1 viral load 
Baseline (n=38, 35) 4.23 (3.89, 4.57) 4.33 (4.11, 4.56) 0.10 (-0.30, 0.51) 
3 months (n=38, 35) 4.23 (3.91, 4.54) 4.45 (4.20, 4.70) 0.22 (-0.18, 0.62) 
6 months (n=36, 35) 4.33 (4.02, 4.65) 4.57 (4.28, 4.87) 0.24 (-0.19, 0.67) 
0-6 month change 0.06 (-0.11, 0.23) 0.23 (0.05, 0.41) 0.17 (-0.08, 0.42) 
Adjusted 0-6 month change‡ 0.14 (-0.07, 0.36) 0.34 (0.12, 0.57) 0.20 (-0.03, 0.43) 
    
Haemoglobin (g/L)‡ 
Baseline (n=38, 35) 116 (112, 121) 116 (111, 120) -0.82 (-6.90, 5.26) 
3 months (n=38, 35) 121 (115, 127) 125 (119, 130) 3.75 (-3.66, 11.2) 
6 months (n=38, 35) 130 (125, 135) 126 (121, 131) -3.53 (-10.4, 3.37) 
0-6 month change 13.6 (10.6, 16.5) 10.5 (6.32, 14.6) -3.13 (-8.21, 1.96) 
Adjusted 0-6 month change‡ 11.4 (8.44, 14.3) 9.66 (5.13, 14.2) -1.71 (-6.49, 3.07) 
* Values shown are mean (95% CI). 
† The between-group difference corresponding to the “0-6 month change” shows the estimated 
additional effect of leaf concentrate powder compared with milk powder, i.e. the interaction 
term between the intervention and 6-month time-point. 
‡ Adjusted for age, sex, all blood parameters, CRP positivity, and height-for-age Z-score. 
Table 4: Anthropometric parameters at baseline, 3 and 6 months 
 Skimmed milk 
powder group 
Leaf concentrate 
powder group 
Between-group 
difference* 
Height-for-age Z-score    
Baseline (n=38, 35) -1.17 (-1.56, -0.78) -1.47 (-1.82, -1.11) -0.30 (-0.82, 0.22) 
3 months (n=38, 35) -0.82 (-1.21, -0.44) -1.14 (-1.52, -0.76) -0.32 (-0.85, 0.22) 
6 months (n=38, 35) -0.63 (-1.03, -0.23) -0.96 (-1.34, -0.58) -0.33 (-0.88, 0.21) 
0-6 month change 0.54 (0.45, 0.62) 0.51 (0.42, 0.60) -0.03 (-0.15, 0.10) 
Adjusted 0-6 month change† 0.53 (0.44, 0.62) 0.48 (0.37, 0.59) -0.05 (-0.18, 0.08) 
    
Weight-for-age Z-score    
Baseline (n=38, 35) -1.36 (-1.80, -0.92) -1.61 (-1.94, -1.29) -0.25 (-0.80, 0.29) 
3 months (n=38, 35) -1.20 (-1.64, -0.75) -1.49 (-1.81, -1.16) -0.29 (-0.84, 0.26) 
6 months (n=38, 35) -1.03 (-1.50, -0.56) -1.35 (-1.76, -0.95) -0.32 (-0.94, 0.29) 
0-6 month change 0.31 (0.19, 0.42) 0.25 (0.02, 0.49) -0.05 (-0.31, 0.21) 
Adjusted 0-6 month change† 0.27 (0.14, 0.39) 0.24 (-0.01, 0.50) -0.02 (-0.26, 0.22) 
    
Handgrip strength (kg)‡    
Baseline (n=38, 35) 10.8 (9.2, 12.7) 11.4 (9.7, 13.5) 1.02 (0.93, 1.13) 
3 months (n=38, 35) 11.1 (9.5, 13.0) 11.7 (9.8, 13.9) 1.02 (0.93, 1.13) 
6 months (n=38, 35) 11.6 (10.2, 13.3) 12.5 (10.7, 14.5) 1.03 (0.95, 1.12) 
0-6 month change 1.73 (0.60, 4.98) 2.59 (1.37, 4.86) 1.49 (0.44, 5.10) 
Adjusted 0-6 month change† 1.76 (0.59, 5.27) 2.40 (1.18, 4.91) 1.36 (0.38, 4.94) 
* The between-group difference corresponding to the “0-6 month change” shows the estimated 
additional effect of leaf concentrate powder compared with milk powder, i.e. the interaction 
term between the intervention and 6-month time-point. 
† Adjusted for age, sex and all blood parameters. 
‡ Values shown for baseline, 3- and 6-month levels of handgrip strength are geometric mean 
(95% CI). Between-group difference and 0-6 month changes are ratios of geometric means from 
linear regression of log-transformed handgrip strength values, e.g. coefficient = 1.10 indicates 
that strength is 10% higher in LCP group compared with SMP group, coefficient = 0.90 indicates 
that strength is 10% lower in LCP group compared with SMP group, coefficient = 1.00 indicates 
no difference/change. 
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